Harmony Biosciences Holdings, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Vanguard Portfolio Management has reported beneficial ownership of over 5% of Harmony Biosciences Holdings Inc. common stock as of June 30, 2026.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Harmony Biosciences Holdings Inc. following an internal corporate realignment.
NASDAQ
FMR LLC and its Chairman and CEO, Abigail P. Johnson, have jointly disclosed a beneficial ownership of 5.4% in Harmony Biosciences Holdings Inc. common stock as of December 31, 2025.
NASDAQ
Valor Equity Partners and affiliated entities, including Antonio J. Gracias and Juan A. Sabater, have filed an amended Schedule 13G indicating their beneficial ownership in Harmony Biosciences Holdings, Inc. is now below 5% for all reporting persons.
NASDAQ
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a 6.7% beneficial ownership stake in Harmony Biosciences Holdings Inc. as of September 30, 2025.
NASDAQ
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 10.1% beneficial ownership stake in Harmony Biosciences Holdings, Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: Valor Entities Maintain Significant Stake in Harmony Biosciences, Disclosing 11.7% Beneficial Ownership
Valor IV Pharma Holdings, LLC and affiliated entities, including Antonio J. Gracias and Juan A. Sabater, have filed an amended Schedule 13G disclosing a collective beneficial ownership of up to 11.7% of Harmony Biosciences Holdings, Inc. common stock as of December 31, 2024.
NASDAQ
Marshman Fund Trust II has reported a beneficial ownership of 10.6% of Harmony Biosciences Holdings, Inc.'s common stock as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 12.2% Passive Stake in Harmony Biosciences
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 12.2% beneficial ownership stake in Harmony Biosciences Holdings, Inc. as of December 31, 2024.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, revealing its beneficial ownership of 8.3% of Harmony Biosciences Holdings Inc.'s common stock as of December 31, 2024.